drugset
drugset / Trial / NCT05277012

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

NCT05277012 ↗

Phase 1 Completed 24 enrolled Arcus Biosciences, Inc. Gilead Sciences · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This study will compare the pharmacokinetics (PK) effect of single-dose etrumadenant tablet and capsule formulations in fasted conditions. The effect of food on single-dose PK of tablet formulation will also be assessed.

Timeline

Start
2022-02-10
Primary completion
2022-03-31
Completion
2022-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Etrumadenant Small molecule — —

Indications

No indication recorded.